牛牛AI助理已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.
Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.
處於開發階段的企業Alterity Therapeutics Limited已於2024年2月15日與瓊斯貿易機構服務有限責任公司簽訂了銷售協議。根據該協議，Alterity Therapeutics可以通過作爲銷售代理的JonesTrading發行和出售美國存托股票（ADS）。根據《證券法條例》第415條的規定，銷售將在 “市場發行” 的基礎上進行。JonesTrading將獲得所售股票總銷售價格的3％的佣金。ADS的發行總額將高達6,000,000美元，此次發行是根據同日向美國證券交易委員會提交的招股說明書補充文件進行的。股票將根據公司在F-3表格上的有效註冊聲明發行。該公司的法律顧問就即將發行的股票的有效性提供了意見，該意見作爲證物包含在報告中。
處於開發階段的企業Alterity Therapeutics Limited已於2024年2月15日與瓊斯貿易機構服務有限責任公司簽訂了銷售協議。根據該協議，Alterity Therapeutics可以通過作爲銷售代理的JonesTrading發行和出售美國存托股票（ADS）。根據《證券法條例》第415條的規定，銷售將在 “市場發行” 的基礎上進行。JonesTrading將獲得所售股票總銷售價格的3％的佣金。ADS的發行總額將高達6,000,000美元，此次發行是根據同日向美國證券交易委員會提交的招股說明書補充文件進行的。股票將根據公司在F-3表格上的有效註冊聲明發行。該公司的法律顧問就即將發行的股票的有效性提供了意見，該意見作爲證物包含在報告中。
有用
沒用